Abstracts Archive - Page 2114 of 2425 - ACR Meeting Abstracts

Abstract Number: 2053 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Intermittent Intra-Venous Cyclophosphamide and Cyclosporin A Combination Therapy For Rapidly Progressive Interstitial Lung Disease With Dermatomyositis Associated With Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody Titer
Noriko Sasaki¹, Shinji Sato¹, Shinichi Nogi¹, Naofumi Chinen², Kiri Honda¹, Eiko Saito¹, Chiho Yamada² and Yasuo Suzuki², ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) autoantibody is present specifically in patients with dermatomyositis (DM), especially those with few or no muscle manifestations (clinically amyopathic…
Abstract Number: 2054 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Low-Intensity Resistance Training Combined With Vascular Occlusion In Polymyositis and Dermatomyositis
Melina Mattar¹, Luiz A. Perandini¹, Thalita Dassouki², Samuel K. Shinjo¹, Bruno Gualano³, Hamilton Roschel³, Fernanda R. Lima⁴ and Ana Lucia S. Pinto¹, ¹University of Sao Paulo, Rheumatology Division, LACRE, Sao Paulo, Brazil, ²Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil, ⁴University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil
Background/Purpose: Previous studies have demonstrated that low-intensity resistance training combined with vascular occlusion (VO) improves muscle strength to the magnitude of traditional high-intensity resistance training…
Abstract Number: 2055 • 2013 ACR/ARHP Annual Meeting
Killer T Cell Inhibition By CD226 Blockade For Treatment Of Inflammatory Myopathy
Hitoshi Kohsaka¹, Nao Tateishi¹, Shinya Hirata², Kazuko Shibuya³, Akira Shibuya³ and Nobuyuki Miyasaka⁴, ¹Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Kumamoto University School of Medicine, Kumamoto, Japan, ³Department of Immunology, University of Tsukuba, Ibaraki, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Current treatment strategy of polymyositis/dermatomyositis calls for administration of high dose glucocorticoids and additional immunosupressants when necessary. These options are based largely on successful…
Abstract Number: 2056 • 2013 ACR/ARHP Annual Meeting
Use Of Biologics In Polymyositis and Dermatomyositis – A National Register Study
John Svensson¹, Anna Tjärnlund², Balsam Hanna³, Sara Magnusson Bucher⁴, Johan Askling⁵, Ingrid E. Lundberg⁶ and Maryam Dastmalchi⁷, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Stockholm, Sweden, ³Rheumatology Unit, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁴Rheumatology unit, Örebro University Hospital, Örebro, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Biologics have been used off-label in treatment of refractory polymyositis (PM) and dermatomyositis (DM). In this study we aimed to describe the use of…
Abstract Number: 2057 • 2013 ACR/ARHP Annual Meeting
Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – The RIM (Rituximab in Myositis) Trial
Ann M. Reed¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla³, Helen Khun², Rohit Aggarwal⁴, Dana P. Ascherman⁵, Marc C. Levesque⁶ and Chester V. Oddis⁷, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The aim of this study was to examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies (autoAbs) as biomarkers of…
Abstract Number: 2058 • 2013 ACR/ARHP Annual Meeting
Evidence For Immunotherapy In Polymyositis and Dermatomyositis: A Systematic Review
Erin Vermaak¹ and Neil J McHugh^1,2, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are rare chronic inflammatory disorders of muscle. The morbidity and mortality associated with these conditions remains significant despite treatment,…
Abstract Number: 2059 • 2013 ACR/ARHP Annual Meeting
Mortality In Polymyositis and Dermatomyositis: A Single Centre Study
Erin Vermaak¹, Gavin Shaddick² and Neil J McHugh^1,3, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Mathematics, University of Bath, Bath, United Kingdom, ³Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
Background/Purpose: PM and DM are rare chronic inflammatory disorders of muscle, and data on long-term prognosis and outcomes are lacking. Previous studies have reported 5-year…
Abstract Number: 2060 • 2013 ACR/ARHP Annual Meeting
Influence Of Anti-Ro/SSA Autoantibodies On Cinical Characteristic Of a Cohort Of Myositis Patients
Simone Barsotti¹, Rossella Neri², Valentina Iacopetti³, Chiara Baldini², Nicoletta Luciano², Antonio Tavoni⁴, Anna d'Ascanio⁵ and Stefano Bombardieri⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Internal medicine, Barga, Italy, ⁴University of Pisa, Immunoallergology Unit, Pisa, Italy, ⁵Malattie muscolo-scheletriche e cutanee, Rheumatology Unit, Pisa, Italy, ⁶Rheumatology Unit, Pisa, Italy
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of acquired diseases, characterized by immunoflogistic processes primarily involving the skeletal muscle. Myositis-associated antibodies are frequently detected…
Abstract Number: 2061 • 2013 ACR/ARHP Annual Meeting
Good Inter-Rater Reliability Of Myositis Experts In Assessing Clinical Improvement
Rohit Aggarwal¹, Nicolino. Ruperto², Brian Erman³, Saad Feroz⁴, Jiri Vencovsky⁵, Adam Huber⁶, Sheila K. Oliveira⁷, Angela Pistorio⁸, Clarissa Pilkington⁹, Angelo Ravelli¹⁰, Brian M. Feldman¹¹, Howard Rockette¹², Frederick W. Miller⁴, Peter A. Lachenbruch⁴ and Lisa G. Rider⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Istituto Gaslini-PRINTO, Genoa, Italy, ³National Institute of Health, Bethesda, DC, ⁴Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ⁵Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, ⁶IWK Health Centre, Halifax, NS, Canada, ⁷PRINTO-Istituto Gaslini, Genova, Italy, ⁸PRINTO, Genoa, Italy, ⁹Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹⁰Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ¹¹Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ¹²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: IMACS and PRINTO have developed preliminary core set activity measures and definitions of improvement (DOIs) for adult or juvenile dermatomyositis (DM) and polymyositis (PM).…
Abstract Number: 2062 • 2013 ACR/ARHP Annual Meeting
Clinical Features and Outcome In Polymyositis Vs. Dermatomyositis Patients With The Anti-Jo-1 Autoantibody
Rohit Aggarwal¹, Diane Koontz², Zengbiao Qi³ and Chester V. Oddis⁴, ¹Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Department of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The clinical characteristics of dermatomyositis (DM) patients possessing the anti-Jo-1 autoantibody (autoAb) are not well known. We analyzed the clinical features and prognosis of…
Abstract Number: 2063 • 2013 ACR/ARHP Annual Meeting
Identification Of Autoantibodies To Tyrosyl–Transfer RNA Synthetase Associated With Anti-Synthetase Syndrome
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Koji Tahara², Kaori Ito², Hiroaki Hattori², Takahisa Gono¹, Kae Takagi¹, Masanori Hanaoka¹, Yuko Ota¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Advanced Medical Technology and Development, BML, Saitama, Japan
Background/Purpose : Autoantibodies directed against the aminoacyl transfer RNA (tRNA) synthetases are associated with myositis, arthritis, Raynaud’s phenomenon, mechanic’s hands, fever, and interstitial lung disease,…
Abstract Number: 2064 • 2013 ACR/ARHP Annual Meeting
An Autoimmune Myositis-Overlap Syndrome Associated With Autoantibodies To Nuclear Pore Complexes ‒ Description and Long-Term Follow-Up Of The Anti-Nup Syndrome
Catherine Isabelle¹, Marie-Christine Dabauvalle², Marvin J. Fritzler³, Ira N. Targoff⁴, Rose Goldstein⁵, Yves Troyanov¹, Michel Gagné¹, Jean-Pierre Raynauld¹ and Jean-Luc Senécal¹, ¹Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²University of Würzburg, Würzburg, Germany, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, ⁵McGill University, Montreal, QC, Canada
Background/Purpose: Autoimmune myositis encompasses various myositis-overlap syndromes, each one being identified by the presence of serum marker autoantibodies. We describe a novel myositis-overlap syndrome in…
Abstract Number: 2065 • 2013 ACR/ARHP Annual Meeting
The Prevalence and Clinical Usefulness Of Anti-NXP-2 Autoantibodies In Chinese Patients With Idiopathic Inflammatory Myopathies
Xin Lu¹, Guochun Wang², Qinglin Peng³, Kai Yuan⁴ and Hanbo Yang⁵, ¹Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, Beijing, China, ²Department of Rheumatology, China-Japan Friendship Hospital, Beijing, China, ³Department of Rheumatology,, China-Japan Friendship Hospital, Beijing, China, ⁴Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China, ⁵Rheumatology, China-Japan Friendship Hospital, Beijing, China
Background/Purpose: To determine the sera levels of anti-NXP-2 antibodies and their clinical association in Chinese patients with idiopathic inflammatory myopathies(IIM). Methods: Sera from 198 Chinese…
Abstract Number: 2066 • 2013 ACR/ARHP Annual Meeting
Distinct Arthropaties In Patients With Anti-Aminoacyl tRNA Synthetase Antibodies: Utility Of Autoantibody Profiles In Discrimination
Yuko Kaneko¹, Hironari Hanaoka¹, Michito Hirakata², Tsutomu Takeuchi¹ and Masataka Kuwana¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Medical Education Center, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Arthritis is observed frequently in patients with anti-aminoacyl transfer RNA synthetase (ARS) autoantibodies and is usually not destructive like rheumatoid arthritis (RA). Despite several…
Abstract Number: 2067 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Associated With Inflammatory Myopathy and Other Systemic Autoimmune Rheumatic Diseases In Sera From Breast Cancer Patients
Monica Vázquez-Del Mercado¹, Adrian Daneri-Navarro², Beatriz Teresita Martín-Márquez³, Raul Vargas Ramirez⁴, Diego Velasco-Sanchez⁵, Jason Y.F. Chan⁶, S. John Calise⁷, Edward K.L. Chan⁷ and Minoru Satoh⁶, ¹Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Hospital Civil JIM, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, ²Laboratorio de Inmunología, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, ³Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Guadalajara, Mexico, ⁴CUCS, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético,, Guadalajara, Mexico, ⁵1. Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, CUCS, Universidad de Guadalajara, Guadalajara, Mexico, ⁶Medicine, University of Florida, Gainesville, FL, ⁷Oral Biology, University of Florida, Gainesville, FL
Background/Purpose: Various autoantibodies have been reported in cancer patients, however, results are inconsistent. In dermatomyositis (DM), striking association between autoantibodies to p155/140 (transcription intermediary factor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].